resveratrol/Finding
One finding, on its own
A single claim from the graph, with the grade computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on alanine aminotransferase
SuggestiveGrade C, Suggestive. Human evidence with several recorded weaknesses, or a design that tops out at C.FindingNull result“Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- meta-analysis
- Dose
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.16 standardised mean difference, 95% CI -0.67 to 0.35
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
Keep reading
- Everything the graph holds on resveratrol
- Every compound studied against Alanine aminotransferase
- How to read the grade and the marks
To cite this finding: https://catalystproject.ai/e/01M3RM65YTTW1GAXYQJ95QB4S6